HAVD

Renaldee has developed a highly effective, affordable, and pharmacologically safe, herbal active vitamin D (AVD) supplement to facilitate the treatment of chronic kidney disease (CKD). CKD is a progressive damage or loss of kidney function that affects >10% of the general population worldwide. In Europe, 50-100 million people suffer from CKD, and predictions suggest that it will become the fifth leading cause of death globally by 2040. CKD patients have exceptionally high rates of vitamin D deficiency (VDD) which is caused by the reduced activity of the kidney to synthesis Calcitriol, the active form of vitamin D. Existing synthetic Calcitriol supplements with narrow therapeutic index have reduced pharmacological tolerance to treat patients with CKD. There is therefore an unmet medical need to develop pharmacokinetically favourable, AVD supplement with an enhanced safety profile to support the treatment of CKD at all stages and prevent further complications. Renaldee’s herbal origin of Calcitriol with favourable pharmacokinetic properties will supplement the body with the essential form of VD that results from the decrease in its own production. This enables the body to function normally in the many functions in which VD plays a role, so that no subsequent damage occurs. This will improve treatment outcome and enhance the physical and mental well-being of CKD patients. The favourable pharmacokinetic properties of Renaldee’s AVD compared to synthetic vitamin D derivatives have been extensively demonstrated in animal models and in human population. The proposed compound will support the treatment of CKD and support bone health in patients with CKD & mineral bone disorder. This will massively decrease the financial and healthcare burden driven by CKD worldwide.